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The NASA Human Research Program’s (HRP) Exploration 
Medical Capability (ExMC) Element is utilizing a Model Based 
Systems Engineering (MBSE) approach to enhance the 
development of systems engineering products that will be used 
to advance medical system designs for exploration missions 
beyond Low Earth Orbit. In support of future missions, the 
team is capturing content such as system behaviors, functional 
decompositions, architecture, system requirements and 
interfaces, and recommendations for clinical capabilities and 
resources in Systems Modeling Language (SysML) models. As 
these products mature, SysML models provide a way for ExMC 
to capture relationships among the various products, which 
includes supporting more integrated and multi-faceted views of 
future medical systems. In addition to using SysML models, 
HRP and ExMC are developing supplementary tools to support 
two key functions: 1) prioritizing current and future research 
activities for exploration missions in an objective manner; and 
2) enabling risk-informed and evidence-based trade space 
analysis for future space vehicles, missions, and systems. This 
paper will discuss the long-term HRP and ExMC vision for the 
larger ecosystem of tools, which include dynamic Probabilistic 
Risk Assessment (PRA) capabilities, additional SysML models, 
a database of system component options, and data 
visualizations. It also includes a review of an initial Pilot Project 
focused on enabling medical system trade studies utilizing data 
that is coordinated across tools for consistent outputs (e.g., 
mission risk metrics that are associated with medical system 
mass values and medical conditions addressed). This first Pilot 
Project demonstrated successful operating procedures and 
integration across tools. Finally, the paper will also cover a 
second Pilot Project that utilizes tool enhancements such as 
medical system optimization capabilities, post-processing, and 
visualization of generated data for subject matter expert review, 
and increased integration amongst the tools themselves. 
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1. INTRODUCTION 
NASA is committed to successfully extending human 
exploration beyond Low Earth Orbit. The Human Research 
Program’s (HRP) Exploration Medical Capability (ExMC) 
Element is utilizing a Model-Based Systems Engineering 
(MBSE) approach to ensure timely input for the development 
of a broadly-scoped, integrated human health and 
performance system for deep space exploration. NASA’s 
future deep space exploration missions mandate a significant 
paradigm change for mission planning, spacecraft design, 
human systems integration, and in-flight medical care due to 
constraints on mass, volume, power, resupply missions, and 
medical evacuation capabilities. These constraints require 
further development of a human health and performance 
system (which includes medical, health and wellness, and 
human systems). The human health and performance system 
will be tightly integrated with mission and habitat design to 
provide a sufficient human health and performance 
infrastructure to enable mission success. ExMC and HRP are 
developing and utilizing a tool suite ecosystem to enhance the 
MBSE approach to support this integration effort.  
 
2. BACKGROUND  
The scope of spaceflight medical systems has historically 
been limited to kits with additional devices manifested as 
needs have arisen. Current medical operations on the 
International Space Station (ISS) are largely reliant on Earth 
for support and decision-making. To extend beyond Low 
Earth Orbit, key changes in the mission characteristics, such 
as reduced mass, power, volume, and data, along with real-
time communication time delays, force a shift to a more 
https://ntrs.nasa.gov/search.jsp?R=20200001532 2020-03-28T19:14:19+00:00Z
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sophisticated medical system. This means reduced initial 
resource allocations, limited or no resupply or augmented 
capabilities using later manifests, increased time/difficulty 
required for removal to definitive medical care, and limited 
real-time operational support [1]. 
Recently, ExMC has been addressing how to inform the 
design of a sophisticated exploration medical system using a 
systems engineering approach [5]. The ExMC Systems 
Engineering team is applying an MBSE application of a 
largely traditional systems “Vee” model, progressing from 
stakeholder engagement, development of a concept of 
operations, defining functions, developing an architecture, 
and writing requirements. Mindock et al discuss those high-
level system engineering efforts in additional detail [4]. 
Current work of the ExMC Systems Engineering team 
includes converging medical system level systems 
engineering products, such as the existing concept of 
operations document, requirements and in process interfaces 
definitions, into a cohesive medical system foundation. This 
foundation is similar to a conceptual baseline, with the 
important distinction that it is based on assumptions for 
exploration missions, and is not a programmatic baseline. It 
is, however, a powerfully solid, defensible, and traceable 
system foundation due to the MBSE approach described 
further in this paper. This foundation can be adjusted by 
future programs as details and plans solidify for specific 
missions. 
The high-level medical system foundation work is not 
sufficient to determine the exact contents and devices to be 
included in a medical system. It shapes and guides the system 
from a “black box” perspective, but key decisions impacting 
the risk accepted by a program due to a specific 
implementation of a medical system will also occur at the 
“white box” level to define what aspects such as medications, 
devices, supplies, and even crew skills, need to be “inside.” 
3. APPROACH 
ExMC has chosen to take a quantitative approach to inform 
the detailed definition of a medical system. This allows for 
evidence based, data-informed decisions when selecting what 
to include in any medical system. To execute a quantitative 
approach, tools are required. The ExMC Systems 
Engineering team has viewed the set of tools as a system 
itself, as the “black box” equivalent of various tools acting 
together to produce cohesive quantitative, analytical outputs. 
This “black box” is referred to as the tool suite, and is further 
discussed in this paper.  
The approach to the tool suite development to date has been 
somewhat non-traditional from the perspective of systems 
engineering practice. In Fiscal Year (FY) 2016, which runs 
from September to September, the initial concepts for 
integrating medical system evaluations were developed [2]. 
In FY2017, work was underway on some of the individual 
tools envisioned as part of the tool suite, but no effort had yet 
been established to integrate development activities across 
the various tools. FY2018 was the first time such an effort 
was undertaken in an initial Pilot Project to help the ExMC 
Systems Engineering team familiarize themselves with the 
desired technical outputs and capabilities of the various tools. 
The technical and organizational value of the initial Pilot 
Project was apparent, and in FY2019 a second Pilot Project 
was initiated to build upon the first and help shape 
stakeholder needs and expectations. At the time of this paper 
writing, parallel work developing more traditional systems 
engineering products has begun in order to focus stakeholder 
convergence on the long-term needs for the tool ecosystem. 
This paper discusses the current tools (as of the end of 
FY2019) and provides an overview of the analytical 
capabilities as exercised in the Pilot Projects. 
4. TOOL ECOSYSTEM OVERVIEW  
The tool suite ecosystem discussed in this paper provides a 
means for the HRP’s ExMC Element’s interests to be 
represented during deep space mission development. The 
long-term goal of the tool suite is to characterize the 
exploration medical system architecture trade space to inform 
mission development, vehicle and habitat development, and 
research planning. It allows the stakeholders to quantify 
engineering impacts and risks that a potential human health 
and performance capability could have on crew and mission 
outcomes. This assessment is done in the context of human 
health and performance missions with a specified 
information flow. The tool suite will follow the flow shown 
in Figure 1.  
 
Figure 1: Tool Suite Information Flow 
In brief, stakeholders will pose a question about a human 
health and performance capability to a tool suite point of 
contact (POC), who will then collect and/or generate the 
information necessary as inputs into the tool suite. The results 
generated by the tool suite will be presented to subject matter 
experts (SMEs), who will then analyze and validate the 
output and provide an interpretation of the results to the POC. 
The POC will then provide the recommendations to the 
relevant stakeholders. Iterations on system options, inputs, 
and outputs may be required. Currently, the tool suite 
provides users with information on risk parameters, resources 
used such as medications, supplies, or devices, health state of 
the crew, and whether relevant metrics are within acceptable 
limits or constraints. 
Within the “Tool Suite” box shown in Figure 1, the current 
tool suite consists of five tools: the Medical Evidence 
Library; the Medical Extensible Dynamic Probabilistic Risk 
Assessment Tool (MEDPRAT); the Medical Item Database 
(MedID); the Exploration Medical System Model (EMSM) 
Tool 
Suite 
SMEs 
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written in the Systems Modeling Language (SysML); and 
post-processing data visualizations created with Excel and 
Tableau. The current block diagram for this tool suite is in 
Figure 2, and a more detailed view of the tool interactions is 
shown in Figure 4. Each tool will be discussed in detail to 
provide a broader overview of this tool suite in development 
for exploration spaceflight missions.  
Evidence Library 
The Evidence Library is a proposed clinical database of 
spaceflight and terrestrial medical evidence. As of the end of 
FY2019, it is still under development. It will include 
intervention options and resources required for each medical 
condition, references for each medical condition, incidence 
of occurrence of medical conditions, and other supporting 
data. The database will be a single library of evidence for 
exploration spaceflight medical condition and health 
outcome data. The ExMC Clinical and Science Team will 
maintain the Evidence Library.  
The inputs to Evidence Library come from a variety of 
sources, including clinical evidence from literature reviews 
by the ExMC Clinical and Science Team, documentation 
of spaceflight medical data from the Lifetime Surveillance 
of Astronaut Health, and candidate resources from MedID. 
While the Evidence Library is still under development, the 
tool suite is using legacy data from the Integrated Medical 
Model’s Medical Evidence Database (iMED). However, 
iMED content is outdated and does not contain the discrete 
data needed to inform the wider array of tools that will be 
utilized in future iterations of the tool suite. 
Medical Item Database 
MedID is a secure, curated, cloud-based database of medical 
items potentially available for exploration spaceflight 
missions. The purpose of MedID is to support and facilitate 
medical system-related evaluations for exploration missions. 
Within the tool suite, it provides the information 
characterizing medical resources (i.e. equipment, 
pharmaceutics) available in candidate medical systems to 
MEPDRAT and generates a Master Equipment List (MEL) 
after MEDPRAT is run. MedID contains mass, volume, 
power, quantity, storage information, and packaging 
information for every resource represented. A use case for 
MedID is shown in Figure 3.  
 
 
 
Figure 3: MedID Use Case 
Figure 3: Tool Suite Interactions 2
EMSM 
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MEDPRAT 
MEDPRAT generates probabilistic predications of human 
health and medical risks during spaceflight under user-
specified mission conditions using historical medical 
evidence from both human spaceflight and terrestrial studies. 
MEDPRAT models discrete events in a dynamic, 
probabilistic simulation, accounting for the effects of 
cascading, unplanned events involving the crew, the vehicle, 
and supporting equipment. MEDPRAT also accounts for the 
positive effects of interventions for treating specific medical 
conditions and countermeasures for mitigating the effects of 
spaceflight. Generally, MEDPRAT assesses spaceflight 
health risks in a manner consistent with the assessment of 
other risk measures in spacecraft design, mission design, or 
decision-making.  
MEDPRAT is extensible, allowing it to work with a wide 
variety of mission scenarios. It has the capability to run with 
an expanding base of medical evidence, with new 
technologies being developed for space medicine, and, 
eventually with domains outside of the medical system, such 
as the exercise system or the life-support system. 
MEDPRAT has three modes of operation for medical 
conditions – fully treated, partially treated (with limited 
medical capability), and untreated – to predict the risks of loss 
of crew life (LOCL), removal to definitive care (RTDC), and 
quality time lost (QTL). These risk metrics provide important 
information about human health and performance. The 
probability of medical conditions occurring is based on a 
given mission scenario, for which assumptions are made on 
the number/gender of crew, pre-existing conditions, and 
number and timing of occurrence of extravehicular activities 
(EVAs).  
MEDPRAT has two primary components known as the 
simulator and the set-selector.  The simulator code is C++ 
based and performs the Monte-Carlo simulations while 
extensively documenting the results of the individual trials.  
These results include both statistical summaries and detailed 
reports of outcomes, which include occurrence of medical 
conditions, usage of medical resources, and courses of 
treatment.   
The set-selector code is Python based and performs global 
optimization to determine the best set of medical resources, 
drawn from an available resources list, which will minimize 
a combination of medical risks while meeting constraints on 
the overall medical system footprint.  These constraints are 
typically acceptable notional target values for mass, volume 
and power consumption, or a combination thereof.  The set-
selector invokes the simulator many times while it pares 
down the medical system from infinite quantities of each 
resource until the footprint is within user-specified 
acceptable targets. The resulting medical set represents a 
feasible, nearly optimized solution.  
EMSM 
An MBSE approach is being implemented with the EMSM, 
which is created in the Object Management Group Systems 
Modeling Language™ (OMG SysML®), a general-purpose 
graphical modeling language for specifying, analyzing, 
designing, and verifying complex systems that may include 
hardware, software, information, personnel, procedures, and 
facilities. The model is populated with cross-correlated 
medical conditions, medical resources, and medical system 
requirements. Based on the relationships between conditions, 
resources, and requirements, the EMSM depicts how 
inclusion or non-inclusion of medical resources translates to 
addressing or not addressing medical conditions and to 
mission medical requirements satisfaction.  
As a graphical modeling language, SysML relies on a defined 
data structure. Within the exploration medical systems 
model, a data structure relevant to the tool suite is captured 
within “stereotypes.” These stereotypes enable the user to 
create domain specific terminology that remains consistent 
throughout the model. The user can also create attributes that 
pertain to each stereotype. An example of a stereotype with 
attributes is shown in Figure 5.   
 
Figure 5: Example of a Stereotype 
In this example from the tool suite EMSM, an IMED 
Resource stereotype was assigned attributes of mass, volume, 
power, quantity, resource category, resource type, and 
consumability. Similarly, an IMED Medical Condition 
stereotype was created and assigned attributes that include 
medical condition name, probabilistic risk information, and 
incident rate. In both cases, other attributes that would make 
each medical resource or condition unique could be added as 
needed to characterize the system. The stereotypes are 
applied to model elements so that information for a unique 
medical condition is related to a unique set of medical 
resources, once a resource has been allocated to the medical 
condition. The allocation dependency matrix is shown in 
Figure 6. 
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The ExMC Clinical and Science Team uses a dependency 
matrix to map the allocations of medical resources to medical 
conditions. They can also utilize their knowledge and 
experience to create a dependency matrix to allocate medical 
resources to a number of other data structures such as clinical 
capabilities or knowledge, skills, and abilities required to 
address medical conditions. Using these dependency 
matrices, the EMSM can suggest what medical conditions 
will be impacted given the loss or removal of a medical 
resource, based on information from MEDPRAT. 
MEDPRAT identifies candidate medical sets containing 
resource removal options arising from user-imposed 
constraints. Results of MEDPRAT analysis are exported into 
an Excel spreadsheet identifying the proposed removed set of 
medical resources for each candidate medical set. This data 
is re-formatted to import the proposed removed set of medical 
resources into SysML and a dependency matrix is used to 
allocate these resources to the appropriate medical conditions 
for comparison. 
The EMSM can then provide a comparison of the two 
candidate medical sets showing the conditions that are 
impacted by the removal of resource, which aids clinicians in 
identifying how the removal of those resources will impact 
the medical capability for addressing a set of medical 
conditions. A screenshot of the EMSM showing this 
capability is shown in Figure 7, in which Scenario 19 and 
Scenario 38 represent the two candidate medical sets with 
different resources. The EMSM additionally includes a 
filtering capability that allows the ExMC Clinical and 
Science Team to determine exceptions between two sets of 
consolidated medical condition lists. The examination of the 
differences between the two candidate medical systems can 
provide insight on which medical outcome is preferred. This 
information can also be presented in tabular form for the 
ExMC Clinical and Science Team review. Similarly, for a 
given resource change, the EMSM has the capability to 
explore how requirements are impacted for a specific 
mission.  
 
Figure 4: Dependency Matrix 
Figure 5: Impacted Medical Conditions 
6
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Post-Processor 
Post-processing includes the use of both Microsoft Excel and 
Tableau data visualization software. There are two post-
processing visualizations built with Tableau, based on the 
outputs from the MEDPRAT set-selector and the MEDPRAT 
simulator runs, respectively. The post-processors present the 
MEDPRAT output data so that stakeholders can make 
expedient, informed decisions based on the results of the 
MEDPRAT run. Once vetted through a clinician, the results 
are then used as input to the EMSM.  
For the MEDPRAT set-selector, the post-processing is used 
to help determine a best candidate medical set to meet all 
constraints and acceptable risk thresholds while being able to 
view the set contents easily. The set-selector post-processor 
is a Tableau workbook linked to an Excel workbook 
containing results from the MEDPRAT set-selector of 
various mission scenarios. It can be modified to be extensible 
to any collection of mission trades with regard to medical 
capability that can be analyzed and simulated by the 
MEDPRAT set-selector. The set-selector post-processor 
allows the ExMC Clinical and Science Team to analyze the 
selected medical system’s mass, volume, contents, and 
descriptions. 
For the MEDPRAT simulator, the post processing is used to 
provide information about condition occurrence, resource 
utilization, and overall medical risks. The simulator post-
processor is a Tableau workbook linked to an Excel 
workbook containing results from the MEDPRAT simulator 
of various mission scenarios. One example of the post-
processing capability for the simulator post-processor is 
shown in Figure 8. 
5. PILOT PROJECT OVERVIEW 
In developing the tool suite, the ExMC Element is conducting 
a multi-phase Pilot Project to demonstrate incremental 
advancement in capability and integration among the various 
tools each fiscal year, beginning in FY2018. Because the 
tools are being developed at multiple NASA Centers under 
different design philosophies, the Pilot Project has adopted 
objectives that relate to integrating the tools into a more 
cohesive whole. 
The ongoing Pilot Project has completed its first and second 
phases. Table 1 lists the goals of the first two phases, while 
Table 2 contains the status of each tool in the tool suite during 
each phase. Table 3 lists the notional target allocation values 
and acceptable risk thresholds assumptions for Phase II, 
which are representative and not programmatic values. In 
Phase I the goals were modest and were intended to 
demonstrate that a user could interact with the tools to 
produce outcomes. The Phase II goals focused on medical 
system optimization, tool and team integration, and more 
substantive trade analysis with the tools. For both phases of 
the Pilot Project it is important to emphasize that developing 
the process is currently valued over results, because the input 
information is notional and incomplete, particularly the 
medical evidence and resource packaging data, which are still 
being gathered. 
 
Figure 8: Top 5 Conditions Influencing LOCL 
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Table 1: Goals of the Phase I and II Pilot Projects
Category Phase I Goal Phase II Goal 
Trade studies 
Remove equipment items from a baseline 
medical set and determine outcomes  
 Perform trades on mission scenarios (length, 
activities, crew histories) 
 Produce an optimal medical set to meet risk target(s) 
while meeting footprint constraint(s) 
 Determine the effect of reducing footprint of heavier 
items through technology development on overall 
risk 
 Demonstrate that optimization can produce a 
medical set that simultaneously meets two cost 
targets (mass, volume) while also meeting two 
acceptable risk thresholds (LOCL, QTL) 
Outcomes 
Produce relevant outputs: 
 Risk metrics (LOCL, QTL, RTDC) 
 Master equipment list 
 Requirements met/unmet by medical 
system 
 Conditions addressed/not addressed by 
medical system 
 Refine outcome fidelity and reporting 
 Fully exercise the MEDPRAT optimization 
capability 
 Visualization of MEDPRAT outcomes in 
Excel/Tableau to assist with decision- making 
 Produce detailed reports from SysML model 
regarding impacts of reduced medical sets 
Formatting Ensure consistent data products across teams Standardize formats and interfaces among the tools 
Process Demonstrate manual process flow  
Identify the interfaces between tools and identify 
opportunities for automation 
Time to results Weeks Days 
Continuous 
improvement 
Document lessons learned going forward 
Adopt a systems engineering approach to the tool suite, 
including a concept of operations  
# of scenarios 2 38 
Table 2: Tool Development Status 
Tool Phase I Pilot Status Phase II Pilot Status 
Evidence 
Library 
Legacy iMED 
information 
Legacy iMED 
information 
MedID 
ISS medical resources 
with legacy iMED 
mass and volume 
information 
Expanded medical 
resources with updates 
to legacy iMED mass 
and volume information 
MEDPRAT Simulator only 
Simulator and set-
selector optimizer in 
place 
EMSM 
Basic reporting of 
impacted conditions 
and requirements 
met/not met 
Phase I capability plus 
the ability to directly 
compare two or more 
trials 
Post-
Processing 
Basic Excel/Tableau 
visualizations 
constructed ad hoc 
Substantial 
development in 
Excel/Tableau to 
enhance visual 
interpretation of data 
and to directly facilitate 
decision making 
 
Table 3: Notional Optimization Targets &  
Risk Thresholds 
Parameter Phase II Pilot Project 
Target Mass Allocation ≤ 12.09 kg 
Target Volume Allocation ≤ 18721 mL 
Acceptable LOCL ≤ 0.001 
Acceptable QTL ≤ 8.4 days 
Acceptable RTDC ≤ 0.05 
 
To meet these goals, the tool suite supported nine different 
trials (A – I) whose Design Reference Mission (DRM), 
medical capability, trade scenarios and qualitative outcomes 
are summarized in Table 4. These trials were selected to be 
representative of a variety of possible trade space scenarios. 
For Phase I the DRM for Trial A was a 42 day mission with 
4 crewmembers, and the DRM for Trial B was a 180-day 
Mars fly-by with 6 crew members, and the baseline medical 
capability was the medical kit for the ISS using data from the 
iMED database for resources. For Phase II trials (C –  I) the 
DRM was a 42-day mission to a cis-lunar habitat, and the 
baseline medical capability was similar to the ISS medical 
kit, but with updated capabilities and values for mass and 
volume from MedID.  
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Table 4: Description and Outcomes of Pilot Project Scenarios 
 
Trial DRM 
Medical 
Capability 
Trade Scenarios Outcomes 
P
h
a
se
 I
 A 
42 days 
4 crew 
1 female 
EVAs 
ISS medical kit 
from iMED 
Remove space motion sickness 
medications from a baseline 
medical set and determine 
outcomes  
 Removing meds resulted in increases in 
LOCL, QTL, and RTDC  
B 
365 days 
6 crew 
1 female 
EVAs 
ISS medical kit 
from iMED 
Remove a significant portion of 
mass/volume by eliminating 
defibrillator and oxygenation 
hardware 
 Removing equipment resulted in non-
significant increases in LOCL, QTL, and 
RTDC  
 32 conditions no longer addressed 
P
h
a
se
 I
I 
C 
42  days 
4 crew 
1 female 
EVAs 
 
Updated medical 
set from MedID 
Investigate effects of: 
 Extend mission to 90 days 
 With/without EVAs 
 With/without RTDC option 
 With/without pre-existing 
conditions among crew 
members 
 Mission duration increase from 42 days to 
90 days contributed significantly to 
increased risk 
 Other effects did not significantly affect 
risk factors for a 42 day mission 
 High variance in outcomes, especially 
LOCL 
D 
42 days 
4 crew  
1 female 
No 
EVAs 
Optimized 
version of Trial C 
 Optimize to meet a mass 
target only. Reduce baseline 
mass target by 12.5% and 
25%.   
 Optimize each combination 
within acceptable LOCL 
only, then within acceptable 
QTL only 
 Optimizing to meet a mass target for 
LOCL only resulted in unacceptably high 
QTL 
 Optimizing for QTL only still resulted in 
acceptable LOCL 
E 
42 days 
4 crew  
1 female 
No 
EVAs 
Optimized 
version of Trial C 
 Optimize to meet a volume 
target only. Reduce baseline 
volume target by 12.5% and 
25%.   
 Optimize each combination 
within acceptable LOCL 
only, then within acceptable 
QTL only 
 Optimizing to meet a volume target for 
LOCL only resulted in unacceptably high 
QTL 
 Optimizing for QTL only still resulted in 
acceptable LOCL 
F 
42 days 
4 crew  
1 female 
No 
EVAs 
Optimized 
version of Trial C 
 Optimize to meet a weighted 
combination of mass and 
volume targets.   
 Optimize each combination 
within acceptable LOCL 
only, then within acceptable 
QTL only 
 Optimizing to meet a combined mass and 
volume target for LOCL only resulted in 
unacceptably high QTL 
 Optimizing to meet a combined mass and 
volume target for QTL only still resulted in 
acceptable LOCL 
 Better overall solution when volume 
weighting was higher relative to mass 
G 
42 days 
4 crew  
1 female 
No 
EVAs 
Optimized 
version of Trial C 
Optimize to meet mass target or 
a weighted combination of 
mass and volume targets and a 
weighted combination of 
acceptable risk thresholds.  
 A weighted combination of risk thresholds 
resulted in the ability to meet both 
simultaneously 
 Better overall solution when volume 
weighting was higher relative to mass 
H 
42 days 
4 crew  
1 female 
No 
EVAs 
Optimized 
version of Trial C 
Optimize to meet a mass target 
with the two heaviest items 
reduced in mass and volume by 
80% each through technology 
development 
 An 80% reduction in mass of two bulky 
items permits their inclusion in the medical 
system and enables medical requirements 
to be met that were previously not being 
met, while maintaining acceptable risk 
I 
42 days 
4 crew  
1 female 
No 
EVAs 
Optimized 
version of Trial C 
Determine the weighting 
coefficients required to meet 
mass and volume targets as 
well as acceptable thresholds 
for LOCL and QTL 
simultaneously.  
 It was possible to meet mass and volume 
targets within acceptable risk thresholds 
for LOCL and QTL 
 The target for volume requires a higher 
weighting because it constrains the 
medical system more than the target for 
mass 
10 
 
Results of selected scenarios 
Loss of resource trades (Trials A and B) – The scenarios 
examined in Phase I dealt specifically with the elimination of 
specific resources and the resulting effects on mission risks. 
The DRM parameters for these trials appear in Table 4. Trial 
A determined that eliminating space adaptation sickness 
medications on a 42-day mission would result in increases in 
risk for LOCL (8.5%), QTL (11.4%), and RTDC (20.3%), 
although only the latter two were statistically significant. 
Trial B found that removing heavier equipment (AED, 
oxygenation hardware) resulted in non-significant increases 
in LOCL (8.5%), QTL (0.4%), and RTDC (1.1%), despite a 
7.4% decrease in mass, and 32 medical conditions that were 
no longer fully treatable.  
Mission trades (Trial C) – Figures 9 and 10 show the effects 
of the binary mission-specific factors (pre-existing 
conditions, extravehicular activities, long duration, and no 
return to definitive care option) on LOCL and QTL. Of the 
four factors, only the long duration factor had a significant 
effect on LOCL (+180%) or on QTL (+263%). All other 
factors produced non-significant differences. LOCL 
demonstrated much higher variance (25% of mean vs. 0.5% 
of mean value, respectively) than QTL throughout all of the 
simulations. 
 
Figure 9: Effects of Binary Mission Trades on LOCL 
 
Figure 6: Effects of Binary Mission Trades on QTL 
 
Optimized trade scenarios (Trials D through I) – The 
quantitative results of the optimization scenarios (17 – 38) are 
summarized in Table 5. In this table, the red numbers do not 
comply with the notional target values. Each of the trade 
scenarios in Trials D through I may be represented as a 
unique combination of either weighting coefficients on either 
cost factors (mass, volume) or risk factors (LOCL, QTL), or 
notional target values for cost factors. RTDC is always 
computed, but it was not used in the Phase II Pilot Project 
weightings. In general, the notional mass and volume targets 
were challenging to meet simultaneously while maintaining 
acceptable risk using the current set of available medical 
resource information, unless the proper combinations of 
weighting factors were employed for the set-selector. Trial D 
focused on mass reduction scenarios whereby the nominal 
baseline mass allocation was reduced from 100% (12.09 kg) 
to 87.5% (10.58 kg) and 75% (9.07 kg). Scenarios 17 through 
19 considered LOCL only as a risk factor, while scenarios 20 
through 22 considered QTL only.  
Trial E focused on volume reduction scenarios whereby the 
nominal baseline volume allocation was reduced from 100% 
(18.3 L) to 87.5% (16.0 L) and 75% (13.7 L). Scenarios 23 
through 25 considered LOCL only as a risk factor, while 
scenarios 26 through 28 considered QTL only. Reducing the 
allocations generally resulted in higher risk factors, with 
LOCL being more sensitive to the reductions than QTL, 
especially when LOCL was not part of the weighted cost 
function. A significant finding is that while optimizing for 
LOCL only, the QTL tends to remain unacceptably high (i.e., 
> 8.4 days). However, the reverse is not true when optimizing 
for QTL only; in this case the LOCL can be brought within 
acceptable thresholds (i.e., < 0.001).   
Weighted combinations of cost factors only in Trial F, 
scenarios 29 through 32, allowed for significant reductions in 
volume but not improved risk performance for the weights 
chosen. Similarly, for weighted combinations of risk factors 
in Trial G, scenarios 33 through 36, the risk performance was 
better, but did not illustrate the tool suite’s ability to meet 
notional cost targets.  
Reducing the mass of two heavy items and forcing their 
inclusion in Trial H resulted in much improved performance 
in meeting all factors, although the notional target volume 
was slightly exceeded.  
The best performance was obtained in Trial I, by intuitively 
changing the weights on the factors until all notional targets 
and acceptable thresholds were met successfully. For this 
particular mission and this set of notional target values, it was 
possible to determine a nearly optimal medical set that met 
all of the constraints. 
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Table 5: Outcomes of Optimized Runs 
Trial Scenario 
Selected  
Set ID 
Cost Factors Risk Factors 
Total Mass 
(kg) 
[Mass weight] 
Total Volume 
(mL) 
[Volume weight] 
RTDC 
[RTDC 
weight] 
LOCL 
[LOCL 
weight] 
QTL (days) 
[QTL 
weight] 
D 
17 14 
12.00 90323 0.132 0.00064 16.6 
1 0 0 1 0 
18 64 
10.57 85893 0.132 0.00044 16.2 
1 0 0 1 0 
19 66 
6.56 70144 0.119 0.0006 16.2 
1 0 0 1 0 
20 49 
11.47 93171 0.008 0.0014 4.8 
1 0 0 0 1 
21 56 
9.68 83318 0.008 0.00102 4.9 
1 0 0 0 1 
22 60 
8.56 82169 0.009 0.00114 4.9 
1 0 0 0 1 
E 
23 110 
4.46 18032 0.132 0.00076 16.5 
0 1 0 1 0 
24 110 
4.15 13197 0.128 0.00074 16.5 
0 1 0 1 0 
25 139 
4.21 13489 0.129 0.00076 16.5 
0 1 0 1 0 
26 96 
6.59 18271 0.086 0.00172 8.3 
0 1 0 0 1 
27 17 
6.01 15702 0.029 0.00122 5.8 
0 1 0 0 1 
28 51 
3.46 11024 0.038 0.00132 5.9 
0 1 0 0 1 
F 
29 49 
9.97 24427 0.131 0.001 17.0 
2 1 0 1 0 
30 59 
8.54 23959 0.134 0.00108 16.6 
1 1 0 1 0 
31 54 
6.74 34099 0.012 0.00132 5.0 
2 1 0 0 1 
32 17 
11.22 96130 0.040 0.00072 6.2 
1 1 0 0 1 
G 
33 31 
12.05 104901 0.024 0.00068 5.4 
1 0 0 2 1 
34 83 
12.05 105029 0.023 0.00064 5.3 
1 0 0 1 1 
35 40 
8.45 26429 0.052 0.00076 6.5 
2 1 0 2 1 
36 55 
5.45 42333 0.036 0.00062 5.7 
2 1 0 1 1 
H 37 59 
6.79 21656 0.039 0.00062 6.1 
2 1 0 2 1 
I 38 41 
4.88 15709 0.041 0.00068 6.1 
1 4 0 1 1 
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Further analysis of the tool suite 
Post-processing tools developed for the tool suite have 
enabled more sophisticated analyses to occur. Figures 11 and 
12 show the LOCL and QTL effects of reducing mass and 
volume while focusing optimization on LOCL, respectively 
(Trials D and E). The LOCL metric is shown by the blue line 
and the QTL metric is represented in orange. These figures 
show that when mass and volume allocations are reduced, 
LOCL is more sensitive to these reductions than QTL due to 
its higher slope. 
 
Figure 7: Effects of Reducing Mass  
 
Figure 8: Effects of Reducing Volume  
Additionally, it is possible to determine the most influential 
medical conditions affecting the risk factors, as shown in 
Figures 13 and 14. These figures illustrate the top five 
conditions of influence for each risk factor, though many 
more influencing conditions exist. It is apparent that the lists 
of conditions influencing each risk factor are very different 
from one another with very little overlap. Optimizing the 
medical system for one factor only will likely be 
accomplished in part at the expense of the other.  
 
Figure 9: Top 5 Conditions Influencing QTL 
 
Figure 10: Top 5 Conditions Influencing LOCL 
A more sophisticated use of the MEDPRAT set-selector 
involves changing the weighting coefficients on cost and 
benefit by guided trial and error until all of the notional cost 
targets and acceptable risk thresholds are met simultaneously 
(Trial I, informed by Trials F and G). The coefficients that 
are ultimately used will be very highly mission-dependent. 
For the DRM used in the Phase II Pilot Project, the cost 
function that produced the desired result was  
Cost = Cmass Mass + Cvolume Volume  (1) 
where Cmass = 1 and Cvolume = 4 and the benefit function was  
Benefit = CLOCL LOCL + CQTL QTL + CRTDC RTDC (2) 
where CLOCL = 1, CQTL = 1, and CRTDC = 0. 
The resulting feasible medical set produced the outcomes 
shown in the last row of Table 5. These values may be 
compared to the notional target values in Table 3. 
Another useful application of the tools requested by the 
stakeholders is a technology development trades to aid in the 
decision making process for the prioritization of research by 
the ExMC Element and HRP. In this scenario, heavy items 
that would normally be left out by the MEDPRAT set-
selector are considered at a fraction of their original footprint 
for possible re-inclusion to the nearly optimal medical set. 
However, it is not guaranteed that the MEDPRAT set-
selector will still retain the item, even at its reduced footprint, 
unless it is specifically instructed to do so by a user-selected 
parameter. This necessitates a four-part simulation approach 
for performing this analysis.   
1. The item(s) under consideration are left at 100% 
footprint, and the set-selector is permitted to 
include/exclude the items based on their cost/benefit 
merit.   
2. A simulation is run with the items set to their original 
benefit, but at zero mass and zero volume. In this case, 
the set-selector retains the items and the resulting 
outcomes define a maximum achievable benefit 
possible with any technology development to reduce 
the item’s (or items’) footprint.   
3. The set-selector is run with the footprint reduced to a 
user-specified target amount and the items are forced to 
be included in the medical set.   
4. The previous simulation is repeated with the set-
selector given the option to include/exclude based on 
merit.   
By comparing the outcomes of all four simulations, one can 
determine the worth of pursuing a technology development 
to reduce the footprint of heavier items.  
In the case of the Phase II Pilot Project, the two items selected 
were the blood pressure/electrocardiogram monitor and the 
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ultrasound machine, and the chosen reduction factor was 
75%. The mass and volume properties of these items are 
shown in Table 6. The notional results of the four-part 
simulation approach for the Phase II Pilot Project are shown 
in Table 7. 
Table 6: Mass and Volume of Heavy Items 
Item 
Mass/Reduced 
Mass (kg) 
Volume/Reduced 
Volume (mL) 
Blood 
Pressure/ECG 
7.9/1.6 28998/7250 
Ultrasound 
Machine 
6.0/1.5 17340/4335 
 
Table 7: Results of Technology Development Trades  
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1 100 No No 5.12 17645 0.038 0.00094 6.04 
2 0 Yes Yes 5.10 17113 0.034 0.00068 5.90 
3 25 Yes Yes 6.55 16836 0.050 0.0009 6.39 
4 25 No No 5.10 17273 0.039 0.0006 6.02 
 
From the notional evidence in Tables 6 and 7, it is apparent 
that given the Phase II Pilot Project’s DRM, available 
resources, medical evidence, and acceptable cost/risk targets, 
there seems little justification for pursuing a 75% reduction 
in mass and volume for the two heavy items. While a more 
drastic reduction may produce a small benefit, it seems 
unlikely that the gain in risk reduction would justify the effort 
in pursuing the technology development. Much of this result 
may be attributed to the relatively short duration of this deep 
space mission, 42 days in length. Perhaps a much longer 
Martian transit mission would produce a result more 
conducive to justifying the technology development, and 
such an analysis is suggested for future work.  
6. CONCLUSIONS 
Summary of Results 
Over the two phases of the Pilot Project, the tool suite has 
demonstrated that for a given DRM, a list of available 
medical resources, and a set of target values for allocation 
and acceptable risk, it can identify a nearly optimal set of 
medical resources that meets all of the notional targets if such 
a solution exists. Additionally, the tool suite can identify 
system requirements and medical conditions and capabilities 
that will be met/unmet by such a medical resource set. This 
capability is important for mission planning, because the very 
worthwhile objective of maintaining crew health and safety 
must be balanced against the realities of limited resource 
capabilities during long duration spaceflight.   
Significance of Work 
The Pilot Project work supports the advancement of a tool 
suite intended to both enable systematic trade study 
evaluations and to inform research priorities.  
The tool suite will assist the ExMC Element to identify which 
medical capabilities have the potential to provide the greatest 
possible risk reduction benefit, leading to an increased 
likelihood of their inclusion in exploration medical systems. 
It can additionally inform NASA mission developers 
regarding the prioritization of research and technology 
development for deep space medical capability, provided that 
the input evidence is of sufficient pedigree to draw 
conclusions regarding the efficacy and applicability of future 
capabilities. Perhaps most importantly, the tool suite enables 
human health and performance to be considered as early as 
possible in the mission planning and vehicle design process, 
allowing for full integration into architectures as they are 
conceptualized, developed, and adopted.  
Limitations  
Key limitations of the current work involve the data and 
model content used in the Pilot Projects. As discussed 
previously, the integration process was prioritized over 
content development for these early efforts in part to help 
identify what the content development needs will be. 
Limitations of each tool are shown in Table 8. 
Table 8: Limitations of Tools 
Tool Limitations 
Evidence 
Library 
Updates to condition incidence rates 
used by MEDPRAT, updates to 
conditions to consider, and updates to 
treatment and resource capabilities are in 
process. 
MedID 
The ServiceNow platform used in Phase 
II was not as configurable as previously 
expected for an operating platform. The 
team is moving towards using an SQL 
database. 
MEDPRAT 
A Susceptibility Inference Network 
(SIN), a capability to capture 
interdependencies among medical 
conditions, is in development to capture 
condition dependencies. 
EMSM 
Incomplete tracing among all applicable 
requirements as the requirements set is 
still in development 
Post-
Processing 
Need for stakeholders to have 
appropriate software to view results  
 
After the conclusion of the Phase II Pilot Project work for the 
tool suite, there were many lessons learned about the 
processes and the tools. A significant limiting factor to the 
work was that data formatting and automation requirements 
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were not captured. Formatting details of .csv files and naming 
conventions should be consistent amongst the tools in the tool 
suite, and they were not consistent at first implementation of 
the data flow process. Additionally, automation capabilities 
were minimal between tools. All inter-tool interfaces are 
candidates for improved automation capabilities.   
A minor limiting factor is that there was not a standardized 
folder structure while compiling data across NASA centers 
or tools in the tool suite. With the team scattered across 
multiple locations, it was difficult for team members to find 
and understand the work that others were doing, the rationale 
behind the work, and how the work would be integrated with 
other elements. 
Additionally, there is a non-trivial learning curve associated 
with each of the tools that should be budgeted and planned 
for by stakeholders. This is a limiting factor for users of the 
tool suite who are outside of the development team. Key 
topics for training new users are shown in Table 9.   
Table 9: Training for Each Tool 
Tool Training 
Evidence 
Library 
Platform is in development, so training 
needs are still to be determined 
MedID SQL, import/export functionality  
MEDPRAT 
Input/output interfaces, computing in a 
cluster environment running UNIX, 
optimizer theory/practice, operation details 
EMSM 
Model content, SysML and MagicDraw 
basics, generating reports, import/export 
functionality 
Post-
Processing 
Tableau (or equivalent), data unions and 
joins, Excel functionalities 
 
Future Work 
In terms of the tool ecosystem capabilities, technology 
assessments of candidate components (Technology 
Readiness Levels – TRL) are yet to be included in Pilot 
Project analyses and are future work to enable informing 
HRP programmatic research priorities. This would allow the 
ExMC element to identify specific items for improvement 
through technology development, which could lead to an 
overall mass/volume footprint reduction and improved 
efficacy. It is the desire that implementing the research 
prioritization capability would eventually lead to the 
reduction of incidence rates through the development of 
preventive countermeasure and improved resources in the 
treatment of medical conditions.  
Automation of the data exchange and operation of tool suite 
runs is also future work, and the team is investigating EMSM 
as one option for the orchestrator. Automation should also be 
included in the MEDPRAT set-selector to choose only one or 
two feasible optimized sets. The ExMC Clinical and Science 
Team is currently involved in this step of the process; 
however, it would only act in the capacity of validating sets 
selected by the tool, if automation is an implemented 
capability. Integration scripts could be written for the 
Evidence Library and MedID tools to MEDPRAT, 
MEDPRAT to the post-processor, and MEDPRAT to 
EMSM. This automation would decrease the overall run time 
of the tool suite and add a decreased dependency on human 
resources.  
Another element of future work is the development of the 
evidence base and models supporting the PRA capabilities. 
The MEDPRAT Susceptibility Inference Network (SIN) that 
is currently in development could be implemented as a 
capability for the tool suite. The SIN defines dependent 
relationships among conditions, which would lead to more 
accurate output data.  
The capability to bundle resources together using resource 
dependencies should also be considered in the future. These 
bundles would allow for resources used for the same medical 
treatment to be tied together, such as the ultrasound machine 
and ultrasound gel. For example, the ultrasound machine is 
frequently left out during set selection, but the ultrasound gel 
is still often retained. These bundles should reside somewhere 
in the tool suite to provide more detailed and accurate output 
data, increasing the fidelity of the trade space analyses 
Additionally, the tool suite can be used to exercise the 
capabilities of the tools further and to assess research and 
development priorities for ExMC and HRP. This could be 
implemented by more extensive simulations of longer 
duration missions, adding potential new capabilities to the 
available resources and evidence library, implementing full 
traceability of requirements in the EMSM and incorporating 
simulations, and expanding the capability of the tools beyond 
just the medical system to include other human health and 
performance system components. These possible expansions 
would build on the work done in the Phase II Pilot Project.  
Planned efforts to create key systems engineering products 
regarding the development of the tool suite will be beneficial. 
These products will help clarify stakeholder needs, the vision 
of the needed system, and key and driving requirements for 
the integrated tool suite ecosystem. Various development 
approaches could be applied to the ecosystem and each of the 
tools, but the ecosystem itself will benefit from additional 
systems engineering efforts to manage the technical and 
organizational interfaces.  
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